GEARBOx - a multisite clinical trial matching tool for children with relapsed or refractory cancer

项目总结/摘要 尽管治愈率稳步上升，但癌症对许多儿童来说仍然是致命的，特别是那些复发或复发的儿童。 难治性疾病精准医疗为这些孩子带来了巨大的希望，但将孩子与可用的 由于缺乏最新信息和高度复杂的合格标准，临床试验仍然是一个挑战 基于临床信息以及基因组和免疫表型生物标记数据。联同 白血病和淋巴瘤协会，儿科癌症数据共享（PCDC）团队开发了GEARBOx （复发时的基因组合格性算法，以获得更好的结果），一种临床试验匹配工具， 为复发性或难治性急性髓细胞白血病患者快速找到潜在的匹配者 （AML）。我们现在奋进扩大GEARBOx，以包括更多的肿瘤类型，包括急性 淋巴母细胞白血病、神经母细胞瘤、横纹肌肉瘤、尤文肉瘤和骨肉瘤。此外，本发明还 我们将通过新的自动化技术， 方法.临床医生可获得的有关试验的信息将得到补充，以包括以下方面的关键数据： 如何快速有效地让孩子参加匹配的研究。最后，PCDC团队将与 第三方流式细胞术实验室（血液学），以创建自动提取和合并结构化 将免疫表型数据直接导入GEARBOx工具。这些改进将极大地增强该过程 为患者找到合适的临床试验，然后让他们参加，从而改善获得关键的 精准治疗

PROJECT SUMMARY / ABSTRACT Despite a steady rise in cure rates, cancer remains deadly for many children, especially those with relapsed or refractory disease. Precision medicine holds great promise for these kids, but matching children to available clinical trials remains a challenge due a lack of up-to-date information and highly complex eligibility criteria based on clinical information and genomic and immunophenotype biomarker data. In collaboration with The Leukemia & Lymphoma Society, the Pediatric Cancer Data Commons (PCDC) team has developed GEARBOx (Genomic Eligibility Algorithm at Relapse for Better Outcomes), a clinical trial matching tool to allow clinicians to quickly find potential matches for their patients with relapsed or refractory acute myelogenous leukemia (AML). We now endeavor to expand GEARBOx to include several more tumor types, including acute lymphoblastic leukemia, neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, and osteosarcoma. Additionally, we will augment the often-manual abstraction of eligibility criteria from clinical trials with new automated methods. The information available to clinicians about trials will be supplemented to include critical data for how to quickly and efficiently enroll a child on a matched study. Finally, the PCDC team will partner with a third-party flow cytometry lab (Hematologics) to create ways to automatically pull and incorporate structured immunophenotype data directly into the GEARBOx tool. These enhancements will greatly enhance the process of finding appropriate clinical trials for patients and then getting them enrolled, thus improving access to critical precision therapy for these children.